Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bacterial Decolonization and Topical Corticosteroid for Radiation Dermatitis
NCT05505214Phase 2Withdrawn
- Sponsor
- Montefiore Medical Center
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of mupirocin, chlorhexidine and mometasone furoate nasal spray in radiation dermatitis (3 arms), sponsored by Montefiore Medical Center. Primary endpoint: Incidence of grade >2 Radiation Dermatitis. Planned start Sep 2023; status: withdrawn.
02
Drugs
mupirocinchlorhexidinemometasone furoate nasal spray
03
Conditions
radiation dermatitis
Beyond the preview
Go deeper on NCT05505214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05505214.